Groups blast Tufts' $2.6bn drug R&D cost analysis
This article was originally published in Scrip
Some groups were having trouble swallowing the $2.6bn figure researchers from the drug industry-funded Tufts Center for the Study of Drug Development (CSDD) declared on 18 November as the cost of developing a new prescription medicine.
You may also be interested in...
The mean R&D investment required to bring a new drug to market was $1.3bn in a new study estimating pharma R&D costs, lower than the $2.8bn frequently cited from a prior study.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.